iMedicare rebrands as Amplicare
Medicare plan comparison software company iMedicare has crafted a new corporate identity alongside revamping and augmenting its pharmacy platform with new tools. The newly dubbed Amplicare said that its platform now includes capabilities beyond Medicare, using patient data to find opportunities where pharmacists can proactively improve patient care.
“There is no change in ownership with the rebranding,” Matt Johnson, COO of New York City-based Amplicare, said. “The same healthcare expert team that is committed to the values of integrity, transparency, and innovation for the empowerment of humanity continue to focus on harnessing structured and unstructured data, presented in user-friendly software interface that enable healthcare providers do what they do best: provide impactful clinical advice and care for their patients.”
The platform now includes Amplicare Connect, which allows pharmacists to create outbound refills in their own voice, as well as Amplicare Restore, which identifies over-the-counter products that a patient might benefit from. Its Amplicare Impact tool that identifies patients who are impacting a pharmacy’s Star Rating measures and Amplicare Assist, which integrates with pharmacy systems to highlight opportunities generated from other Amplicare tools, also now augment the iMedicare plan comparison tool.
“At Amplicare, we work at the intersection of technology and healthcare,” CEO Flaviu Simihaian said. “We are excited about our new brand and continue to use our energy and knowledge to keep breaking down the complex barriers in health care. We strive to make healthcare more open, transparent, and accessible to all.”
The company also offers free webinars to explain the Amplicare platform on its website.
Canada’s generics org names new chair
The Candian Generic Pharmaceutical Association has a new chair. The Toronto-based organization unanimously elected Peter Hardwick, Apotex chief commercial officer and executive vice president, as its chair. Pharmascience COO Jean-Guy Goulet remains vice chair and Sandoz Canada president and general manager Michel Robidoux continues to be chair of the Board of Biosimilars Canada.
“The generic pharmaceutical industry and our partners in the supply chain are facing significant challenges to our sustainability in Canada,” Hardwick said. “Ensuring a stable, predictable market for our companies and the continued supply and introduction of cost-saving generic prescription medicines must remain our key focus.”
Hardwick’s role will involve implementing the five-year initiative between CGPA and the pan-Canadian Pharmaceutical Alliance, as well as an agreement between CGPA and the government of Quebec.
“The recent agreements with pCPA and Quebec will provide billions of dollars in additional savings to Canada’s health-care system,” Hardwick said. “As these significant further price discounts come into effect, we must work with governments and payers to put in place the regulatory and market environment that will ensure the continued and future supply of cost-saving generic medicines.”
Hardwick, who has been with Apotex since 2006 and has more than 25 years of experience in the pharmaceutical industry, noted that generics prices have been reduced recently and that the organization’s work should now be focused on increasing their use.
“Many of the most widely prescribed generic drugs offer a massive 90 percent discount from the prices of the equivalent brand-name versions, but price doesn’t matter if they’re not being used,” he said. “We want to work with Canadians to implement strategies to increase the use of generic prescription medicines so that the savings provided by these lower prices can be fully realized.”
Impax intros generic Estrace Cream
Impax Labs has launched its generic Estrace Cream (estradiol vaginal cream, 0.01%). The product is indicated to treat moderate-to-severe vaginal changes due to menopause.
Impax’s manufacturing and development partner for the generic Estrace Cream, Perrigo, received Food and Drug Administration approval in January. The product had U.S. sales of roughly $469 million for the 12 months ended January 2018, according to data from IQVIA.